SOF-SKN manufacturing begins to ensure clinical trial readi
Open PDF
| Stock | Noxopharm Ltd (NOX.ASX) |
|---|---|
| Release Time | 9 Jun 2026, 8:29 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Noxopharm Begins SOF-SKN Manufacturing for Clinical Trials
Key Points
- Manufacturing process has started
- Expected to take several weeks
- Low supply chain risks
Full Summary
Noxopharm Limited, a clinical-stage biotech company, has announced the commencement of SOF-SKN manufacturing in preparation for a planned clinical trial later this year. The manufacturing process, which is expected to take several weeks, includes quality control checks and utilizes a controlled environment. This efficiency is supported by a favorable active ingredient stability profile, ensuring low supply chain risks. The company plans to use the manufactured product for preclinical investigations and further characterization of SOF-SKN, which is initially being developed for cutaneous lupus erythematosus (CLE) and may expand to other autoimmune-related skin diseases.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In